...
首页> 外文期刊>Journal of Medicinal Chemistry >Dihydrofolate Reductase Mutant with Exceptional Resistance to Methotrexate but Not to Trimetrexate
【24h】

Dihydrofolate Reductase Mutant with Exceptional Resistance to Methotrexate but Not to Trimetrexate

机译:二氢叶酸还原酶突变体对甲氨蝶呤具有极强的抗药性,但对三甲曲呤没有抗药性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Two double (F31A/F34A, I60A/L67G) and one quadruple (F31A/F34A/I60A/L67G) mutant murine dihydrofolate reductases were constructed and evaluated for their ability to impart antifolate resistance. Both 160A/L67G and F31A/F34A/I60A/L67G were found to be unstable and devoid of catalytic activity. The K_i values for F31A/F34A, methotrexate (MTX), bis-MTX, and PT-523 were found to be 10100-, 4410-, and 617-fold higher than the wild-type enzyme, respectively, but only 13.5-fold higher for trimetrexate (TMTX). These findings suggest that F31A/F34A could be used for gene therapy to render normal cells resistant to MtX but sensitive to TMTX.
机译:构建了两个双重(F31A / F34A,I60A / L67G)和一个四个(F31A / F34A / I60A / L67G)突变鼠二氢叶酸还原酶,并评估了它们赋予抗叶酸能力。发现160A / L67G和F31A / F34A / I60A / L67G都不稳定并且没有催化活性。发现F31A / F34A,甲氨蝶呤(MTX),bis-MTX和PT-523的K_i值分别比野生型酶高10100-,4410-和617倍,但仅高13.5倍。三甲蝶呤(TMTX)更高。这些发现表明,F31A / F34A可用于基因治疗,以使正常细胞对MtX具有抗性但对TMTX敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号